rhG-CSF resistant neutropenia in SLE

rhG-CSF resistant neutropenia in SLE.

G-CSF and GM-CSF in Neutropenia.

G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias. ...

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and rhG-CSF in the treatment of a child with severe chronic neutropenia.

Recombinant human granulocyte colony-stimulating factor (rhGCSF) has been widely and successfully used in treating childhood congenital or idiopathic neutropenia.' Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) has been less commonly and, in some patients in whom it failed, rhGCSF was able to restore normal granulocyte count? We report a case with a negative respo...

Neutropenia and G-CSF in lymphoproliferative diseases

BACKGROUND Chemotherapy-induced neutropenia is a major cause of morbidity and mortality. It frequently causes dose reductions or treatment delay, which can be prevented or treated by the administration of granulocyte-colony-stimulating factor (G-CSF). However, a better knowledge of the incidence, day of onset after therapy, and duration of neutropenia is essential to optimize the use of G-CSF. ...

Long-term safety of filgrastim (rhG-CSF) administration

This journal recently included an article by Bennett et al (2006) reporting five cases of haematological malignancy occurring in normal individuals following exposure to haematopoietic growth factors. Three cases described lymphoid malignancies (non-Hodgkin lymphoma and chronic lymphocytic leukaemia) occurring months to years after receipt of an investigational agent (pegylated, recombinant meg...